Literature DB >> 24491803

miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation.

Michael P Hell1, Claudio R Thoma, Niklaus Fankhauser, Yann Christinat, Thomas C Weber, Wilhelm Krek.   

Abstract

Chromosomal instability enables tumor development, enabled in part by aberrant expression of the mitotic checkpoint protein Mad2. Here we identify a novel regulatory mechanism for Mad2 expression involving miR-28-5p-mediated inhibition of Mad2 translation, and we demonstrate that this mechanism is triggered by inactivation of the tumor suppressor VHL, the most common event in clear cell renal cell carcinoma (ccRCC). In VHL-positive cancer cells, enhanced expression of miR-28-5p diminished Mad2 levels and promoted checkpoint weakness and chromosomal instability. Conversely, in checkpoint-deficient VHL-negative renal carcinoma cells, inhibition of miR-28-5p function restored Mad2 levels, mitotic checkpoint proficiency, and chromosomal stability. Notably, chromosome missegregation errors and aneuploidy that were produced in a mouse model of acute renal injury (as a result of kidney-specific ablation of pVHL function) were reverted in vivo also by genetic inhibition of miR-28-5p. Finally, bioinformatic analyses in human ccRCC associated loss of VHL with increased miR-28-5p expression and chromosomal instability. Together, our results defined miR-28-5p as a critical regulator of Mad2 translation and mitotic checkpoint function. By identifying a potential mediator of chromosomal instability in VHL-associated cancers, our work also suggests a novel microRNA-based therapeutic strategy to target aneuploid cells in VHL-associated cancers. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24491803     DOI: 10.1158/0008-5472.CAN-13-2041

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology.

Authors:  Tianying Xing; Huiying He
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 2.  miRNA dysregulation is an emerging modulator of genomic instability.

Authors:  Ana P Ferragut Cardoso; Mayukh Banerjee; Alexandra N Nail; Angeliki Lykoudi; J Christopher States
Journal:  Semin Cancer Biol       Date:  2021-05-09       Impact factor: 15.707

3.  Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma.

Authors:  Wenqiang Zhang; Ruiyu Liu; Lin Zhang; Chao Wang; Ziyan Dong; Jiasheng Feng; Mayao Luo; Yifan Zhang; Zhuofan Xu; Shidong Lv; Qiang Wei
Journal:  Cancer Gene Ther       Date:  2021-04-23       Impact factor: 5.854

Review 4.  MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Oncol Rep       Date:  2015-02-13       Impact factor: 3.906

Review 5.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

Review 6.  Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis.

Authors:  Pauline Hascoet; Franck Chesnel; Cathy Le Goff; Xavier Le Goff; Yannick Arlot-Bonnemains
Journal:  Front Oncol       Date:  2015-10-27       Impact factor: 6.244

7.  Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.

Authors:  Mahesh Tambe; Sofia Pruikkonen; Jenni Mäki-Jouppila; Ping Chen; Bente Vilming Elgaaen; Anne Hege Straume; Kaisa Huhtinen; Olli Cárpen; Per Eystein Lønning; Ben Davidson; Sampsa Hautaniemi; Marko J Kallio
Journal:  Oncotarget       Date:  2016-03-15

Review 8.  MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Lisa-Maria Schanza; Maximilian Seles; Michael Stotz; Johannes Fosselteder; Georg C Hutterer; Martin Pichler; Verena Stiegelbauer
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

9.  Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.

Authors:  Liang-Liang Li; Li-Li Qu; Han-Jiang Fu; Xiao-Fei Zheng; Chuan-Hao Tang; Xiao-Yan Li; Jian Chen; Wei-Xia Wang; Shao-Xing Yang; Lin Wang; Guan-Hua Zhao; Pan-Pan Lv; Min Zhang; Yang-Yang Lei; Hai-Feng Qin; Hong Wang; Hong-Jun Gao; Xiao-Qing Liu
Journal:  Oncotarget       Date:  2017-07-11

10.  miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion.

Authors:  Qing Li; Nathan Johnston; Xiufen Zheng; Hongmei Wang; Xusheng Zhang; Dian Gao; Weiping Min
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.